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Risk stratification for accurate identification of ADHF patients at high risk for readmission and mortality may enable clinicians to undertake timely interventions: triage to appropriate level of care and resource allocation for postdischarge care. Further risk stratification may allow the care team to plan and implement a personalized care plan. Several clinical and laboratory variables have been proposed for identification of patients with ADHF who are at increased risk for adverse clinical outcomes. Despite advances in the risk stratification of patients with ADHF, the accurate prediction of individuals at high risk for readmissions and mortality is challenging. Cardiac troponin T (cTnT) and I (cTnI) are highly sensitive and specific biomarkers that are widely used for the risk stratification of patients with acute myocardial infarction and stable heart failure. 2 In this systematic review and meta-analysis, we evaluate circulating cardiac troponin in determining risk for increased length of stay (LOS), hospital readmission, and mortality among patients admitted with ADHF.
METHODS Data Sources and Searches
This systematic review and meta-analysis was conducted in accordance with the established methods 3 and Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. 4 Risk of bias was evaluated using the Newcastle-Ottawa Scale for cohort studies. 5 We performed a comprehensive search of several databases from each database's earliest inception to March 2015 without language restrictions. The databases included MEDLINE InProcess & Other Non-Indexed Citations, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. We conducted a manual search for bibliography of pertinent reviews for relevant citations that our electronic searches might have missed. The actual strategy is available from the corresponding author.
with ADHF, (2) comparator groups stratified by cardiac troponin (cTn) level as defined by individual study investigators, and (3) studies reporting 1 or more of the following clinical outcomes: (1) inhospital mortality, (2) hospital LOS, (3) major adverse events during hospitalization (defined as persistent dyspnea, 6 worsening of heart failure, [6] [7] [8] [9] worsening of renal function [creatinine 0.3 mg/dL], 8 or recurrent myocardial ischemia 9 after hospitalization for ADHF), (4) postdischarge readmission, (5) postdischarge mortality rate, and (6) the composite of readmission and mortality. We excluded studies incorporating patients with (1) stable heart failure, (2) acute myocarditis, (3) chemotherapy-induced cardiomyopathy, (4) postsurgical heart failure, (5) transplanted heart, (6) left ventricular assist device, and (7) hemodialysis.
We incorporated the description of ADHF from national registry for defining ADHF. 10 The lower limit of detection of cTn level in healthy subjects is assay dependent, each with a different cutoff value. To improve uniformity of expression in the present metaanalysis, we arbitrarily stratified groups by the level of cTn: (1) undetected cTn (cTnT <0.01; cTnI <0.012 lg/L), (2) detectable cTn (cTnT 0.01-0.03; cTnI 0.012-0.03 lg/L), and (3) elevated cTn (cTnT >0.03; cTnI >0.034 lg/L).
Data Extraction and Risk of Bias Assessment
From the results of the initial search, 2 investigators (M.Y. and A.D.A), working independently, reviewed articles for eligibility on the basis of titles and abstracts. Studies that satisfied the inclusion and exclusion criteria were retrieved for full-text review. Disagreements were resolved by consensus after discussion among investigators, and retained conflicts were adjudicated by a third investigator.
We extracted the following data from each study: type of study, number of participants, age, gender, type of cTn assayed and cut point, comorbidities, length of follow-up, and outcome measure. Prevalence of detectable or elevated cTn, measure of association with clinical outcomes (hazard ratio [HR], odds ratio [OR], or relative risk) were also abstracted. When HR or OR were not reported for an outcome, based on other provided data, we estimated HR using previously validated methods.
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Data Synthesis and Analysis Studies were stratified by cTn cutoff point and length of follow-up. To reduce heterogeneity, studies reporting clinical outcomes at multiple time periods after the index hospitalization were grouped in three categories: (1) studies with short-term follow up (0-6 months), (2) studies with intermediate-term follow-up (up to 1 year), and (3) studies with long-term followup (up to 3.5 years). We used the DerSimonian and Laird random effects model to combine OR or HR reported by individual studies. The consistency of the results of the studies was assessed by I 2 statistics, with values >40% considered as indicators of heterogeneity. We evaluated statistically for publication bias if a sufficient number of studies was available, because such evaluation is unreliable when<20 studies are included in a particular analysis. 12 Sensitivity analyses were performed to investigate the robustness of results to a few assumptions. Analyses were repeated excluding studies reporting unadjusted relative effect measures to assess whether confounding had a large effect on overall results. Similarly, analysis was repeated omitting studies reporting detectable cTn as opposed to elevated cTn level to assess whether these studies influence overall results. All statistical analyses were conducted using Stata 14.0 (StataCorp, College Station, TX).
Quality and Risk of Bias Assessment
The Newcastle-Ottawa scale was used to assess the quality and risk of bias in cohort studies as suggested by the Cochrane Collaboration. 13 For the assessment of risk of bias, a study was awarded a maximum of 1 star for each of the 7 items from 2 domains: (1) selection of cohort (representativeness of the exposed cohort, selection of the nonexposed cohort, ascertainment of exposure, and demonstration that the outcome of interest was not present at the start of the study) and (2) outcome (assessment of outcome, was the follow-up long enough, adequacy of the follow-up of the cohort), and a maximum of 2 stars for comparability of the cohort (comparability on the basis of design and analysis) ( Table 1) . Figure 1 represents the PRISMA flow diagram for literature search and selection process to identify eligible studies for inclusion.
RESULTS

Search Results
Characteristics of Included Studies
We identified 26 studies, which were all observational cohorts with postdischarge median follow-up from 30 days to 472 days. Table 2 summarizes the study characteristics. Studies were heterogeneous with regard to prevalence of elevated cTn, cTn assay, and length of follow-up. Thirteen were single-center and 5 were multicenter studies, 4 were substudies of large multicenter phase III clinical trials, and 4 were registries. Except for one abstracts, all studies were peer-reviewed publications. Sample size ranged from 34 to 69,259 patients. Table 3 stratifies the characteristics of study populations by cTn status. The studies included 77,297 participants hospitalized for ADHF, of whom 7176 (9.3%) had detectable or elevated cTn level. Twentyfive studies reported data on type of cTn measured (cTnI, cTnT, or both) and reported cutoff values for detectable or elevated cTn ( Table 3) . The percentages of patients who had detectable or elevated cTn varied widely across the studies (6.2%-68%). Most studies utilized standard assays, and the cutoff point for cTn level was chosen arbitrary by study investigators or derived from receiver operating characteristic curve analysis. cTn level is assay dependent. For instance, the 99th centile upper reference limit (URL) is 0.014 ng/mL for cTnT with the Roche high-sensitivity cTnT assay, and 0.04 ng/mL with the Siemens cTnI-ultra assay. Few studies of the present meta-analysis incorporated a cTn cutoff point that defined acute myocardial infarction. 14 Nine studies used a lower threshold cTn level (cTnT >0.01->0.03; cTnI >0.03) for stratification into comparator groups.
Twenty-five studies reported performance of cTn as a dichotomized variable. A few studies, additionally, examined clinical outcome in patients grouped by tertiles by cTn and determined the dose-response relationship using cTn as a continuous variable. The measure of association between cTn and clinical outcome was reported as HR or OR by 16 studies. The remaining 6 studies reported the number of clinical events in the groups by cTn level and therefore provided unadjusted estimates. The results of all metaanalyses are depicted in Figure 2 .
In-hospital Clinical Outcomes
Three studies examined the association between cTn level and LOS. 6, 15, 16 One study (n 5 808) found increased LOS among patients with elevated cTn. 6 Another study (n 5 141), which tested the cTn level as a continuous variable, reported no statistically significant association between cTn level and LOS. 16 A large, multicenter ADHF registry (Acute Decompensated Heart Failure National Registry), which reported elevated cTn as a predictor of LOS (mean stay 6.6 vs 5.5 days; P < 0.001) but did not provide binary data (OR, confidence interval [CI]), was therefore excluded from the meta-analysis. 15 The pooled HRs from 2 studies revealed a significant increase in LOS in the cohort with elevated cTn (OR: 1.05, 95% CI: 1.01-1.10, P 5 0.06, I 2 5 59.5.0%, n 5 949). Six studies assessed in-hospital mortality, 15, [17] [18] [19] [20] [21] and the metaanalysis showed a significant increase in the risk of death with no significant heterogeneity (OR: 2.57, 95% CI: 2.27-2.91, P 5 0.744, I 2 5 0.0%, n 5 69,524). Similarly, 4 clinical studies [6] [7] [8] [9] found detectable or elevated cTn as a predictor of worsened composite clinical outcomes of death and major cardiovascular events (OR: 1.33, 95% CI: 1.03-1.71, P 5 0.473, I 2 5 0.0%, n 5 1,313).
Short-term (0 to 6 Months) Clinical Outcomes Short-term clinical outcome was assessed in 13 studies. 6, 8, 16, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Nine studies addressed mortality, 6, 16, [23] [24] [25] [26] [27] [28] 30 2 studies readmission, 16, 26 and 7 studies a composite of readmission and mortality during 6 months postdischarge. 6, 8, 21, 22, 24, 26, 29 The meta-analysis showed increased mortality without significant heterogeneity (OR: 2.11, 95% CI: 1.43-3.12, P 5 0.000, I 2 8.5%, 9 studies, n 5 3471) and an increase in the composite of readmission and mortality with significant heterogeneity (OR: 2.81, 95%CI: 1.60-4.92, P 5 0.000, I 2 89.1%, 7 studies, n 5 2028) among ADHF patients with detectable or elevated cTn. The association between cTn level and readmission rate over 6 months post-discharge did not reach statistical significance (OR: 1.00, 95% CI: 0.37-2.74, P 5 0.034, I 2 77.9%, 2 studies, n 5 641).
Intermediate-term (Up to 12 Months) Clinical Outcomes
Intermediate-term (during the 12 months postdischarge) clinical outcome was assessed in seven studies. 18, 24, [31] [32] [33] [34] [35] Five studies reported an association between cTn level and mortality. 18, 24, 32, 34, 35 The metaanalysis demonstrated an increase in mortality with significant heterogeneity (OR: 2.21, 95% CI: 1.46-3.35, P 5 0.048, I 2 58.4%, 5 studies, n 5 2801). The pooled HRs of 2 studies examining the association between cTn and readmission rate 18, 32 did not yield statistical significance (OR: 1.55, 95% CI: 0.96-2.52, P 5 0.233, I 2 29.6%, 2 studies, n 5 590). A meta-analysis of 5 studies that assessed an association between cTn and outcome 18, 24, [31] [32] [33] showed a significant increase in the risk of composite of readmission and mortality without significant heterogeneity (OR: 2.30, 95% CI: 1.78-2.99, P 5 0.666, I 2 0.0%, 5 studies, n 5 905) among patients with a detectable or elevated cTn.
Long-term (>1 Year) Clinical Outcomes
Long-term clinical outcome was assessed in 7 studies. 18, 19, 21, 24, 28, 36, 37 The meta-analysis of 6 studies 18, 19, 21, 28, 36, 37 demonstrated an increase in mortality without significant heterogeneity (OR: 3.69, 95% CI: 2.64-5.18, P 5 0.696, I 2 0.0%, 6 studies, n 5 1891) among ADHF patients with a detectable or elevated cTn. Likewise, a composite of readmission rate and mortality was also increased (OR: 3.49, 95% CI: 2.08-5.84, P 5 0.070, I 2 57.5%, 4 studies, n 5 448) in a meta-analysis of 4 studies. 18, 21, 24, 37 The meta-analysis of 4 studies 18, 19, 24, 37 that assessed the association between cTn level and readmission rate over long-term follow-up showed no significant association (OR: 2.60, 95% CI: 0.80-8.44, P 5 0.000, I 2 99.9 %, 4 studies, n 5 576).
Confidence in the Estimates
Following the Grading of Recommendations Assessment, Development, and Evaluation approach to evaluate the confidence in the estimates from a systematic review and meta-analysis 38 (ie, certainty or strength of evidence), we found that the association of a detectable or elevated troponin with mortality and readmission is moderate. This is due to a large effect (ie, relative association measure >2.0) demonstrated in observational studies. The confidence in the estimate of association with hospital LOS is low (smaller magnitude of effect). Analyses of in-hospital outcomes were not associated with statistical heterogeneity, whereas several posthospital analyses had statistically significant heterogeneity.
DISCUSSION
We conducted a systematic review and meta-analysis of published studies to assess the association between level of cTn and clinical outcomes including LOS, in-hospital mortality, and short-, intermediate-, and long-term readmission and death following index hospitalization for ADHF. The results of our meta-analysis showed that compared with negative or not-elevated cTn, detectable or elevated cTn was associated with increased LOS and higher rates of in-hospital death among patients with ADHF. In addition, mortality and composite of mortality and readmission at short-, intermediate-or long-term after index hospitalization were greater in ADHF patients with a detectable or elevated cTn, as compared with those without elevated cTn, with significant heterogeneity across the studies. Finally, relatively fewer studies examined the association between cTn and readmission rate at multiple time periods after index hospitalization for ADHF, and these associations did not reach statistical significance. In a review of 67,924 patients with ADHF from the US National Registry, which was limited in assessing inpatient mortality, Peacock et al. reported that a positive cardiac troponin test was associated with higher in-hospital mortality, independently of other predictive variables. 15 We confirmed this observation in the 15, 35 Findings of previous studies showed that ADHF patients with persistently elevated cTn, measured at multiple time points during or following hospitalization, had worse clinical outcomes than did patients without similar elevation in cTn. 24, 29 Conversely, a decline in cTnT levels on serial measurements was associated with lower rates of adverse clinical outcomes, potentially through alleviation in ongoing myocardial injury. 39 Additionally, elevated cTn in ambulatory heart failure patients predicted incident hospitalization for acute decompensation. 40 Acute myocardial injury reflected by elevated cTn can be hypothesized to promote ventricular remodeling and thereby heart failure progression and consequent adverse clinical outcomes. Consistent with this hypothesis, a rise in cTn was observed in conjunction with elevated biological markers that characterize extracellular matrix remodeling in patients with heart failure during the acute and postacute phase. 41, 42 cTn is released in blood in direct proportion to myocardial injury. 43 A rise or fall in cTn with 1 value at or above the 99th centile URL in conjunction with clinical evidence of myocardial injury defines acute myocardial infarction.
14 Although patients with chronic stable heart failure often have chronically elevated cTn, those with ADHF may demonstrate an acute rise in cTn, with values reaching above the 99th percentile of URL in the absence of acute myocardial infarction. 15, 44 The pathophysiology of elevated cTn in ADHF is probably multifactorial. 14, 45, 46 The prevalence of elevated cTn in ADHF varied with assay sensitivity and the cutoff point chosen. For instance, in an analysis of >105,000 patients with ADHF, the prevalence of elevated cTn was increased from 6.2% with higher (cTnI >1.0 ng/mL or cTnT >0.1 ng/mL) to 75% with a lower cutoff point for cTn levels (cTnI >0.4 ng/mL and cTnT >0.01 ng/mL). 15 In the general population with no established coronary artery disease, the prevalence of elevated cTn is contingent on sensitivity of the assay, age, and gender. [47] [48] [49] [50] Elevated cTn, beyond conventional risk factors, identifies a subgroup of individuals from the general population who are at high risk for incident heart failure and death. 51 Furthermore, elevated cTn is an independent predictor of short-and long-term cardiovascular events in patients presenting to an emergency department (ED) for ADHF. 52, 53 In 2 large Canadian registries, an elevated cTn was associated with increased risk of death and cardiovascular readmissions at 30 days after ED visit. 53 A number of recent studies have identified numerous other biomarkers as independent prognostic indicators in patients with heart failure. cTn, when combined with other biomarkers reflecting different dimensions of heart failure pathophysiology such as brain natriuretic peptide (BNP)/N-terminal pro-brain natriuretic peptide, soluble ST2, or cystatin C, enhanced the model's predictive utility beyond individual markers. For instance, patients with elevated cTn who also have increased BNP (840 pg/mL) had in-hospital mortality of 10.2%, which was significantly greater than the 4.4% in patients with elevated BNP without detectable cTn. 54 Additionally, elevated cTn along with elevated pro-brain natriuretic peptide and cystatin C has been reported to offer incremental prognostic information in patient with ADHF. 33 The present systematic review and meta-analysis is the most comprehensive to date and incorporated many observational cohorts with heterogeneous and unselected patient population. The studies have used various commercially available assays for the measurement of cTnT and cTnI. Therefore, findings of this metaanalysis are applicable to a wider heart failure patient population. This review has several limitations. The association of elevated cTn and clinical outcome is likely affected by several confounders. Although we used adjusted estimates when possible, we did not have individual participant data. Due to the small number of included studies in each analysis, we could not explore heterogeneity causes using subgroup analysis or metaregression. For the same reasons, we could not statistically evaluate publication bias, which is likely in the setting of observational studies. The meta-analysis is mainly driven by a few large studies.
In summary, in a broad spectrum of patients with ADHF, a detectable or elevated cTn is an independent predictor of major adverse clinical events not only during acute-phase hospitalization but also after stabilization during the postdischarge phase. cTn is a widely available and inexpensive biomarker that provides important prognostic information and is likely to have important implications for in-patient care and postdischarge surveillance of patients hospitalized for ADHF.
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